Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

2.

Splicing Defects of the Profilin Gene Alter Actin Dynamics in an S. pombe SMN Mutant.

Antoine M, Patrick KL, Soret J, Duc P, Rage F, Cacciottolo R, Nissen KE, Cauchi RJ, Krogan NJ, Guthrie C, Gachet Y, Bordonné R.

iScience. 2020 Jan 24;23(1):100809. doi: 10.1016/j.isci.2019.100809. Epub 2019 Dec 28.

3.

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S.

Haematologica. 2020 Mar;105(3):e95-e97. doi: 10.3324/haematol.2018.215582. Epub 2019 Aug 14. No abstract available.

4.

Compared efficiency of trauma versus scheduled orthopaedic surgery operating rooms in a university hospital.

Rodriguez T, Wolf-Mandroux A, Soret J, Dagneaux L, Canovas F.

Orthop Traumatol Surg Res. 2019 Feb;105(1):179-183. doi: 10.1016/j.otsr.2018.10.019. Epub 2019 Jan 11.

5.

Transmission Attenuation Power Ratio Analysis of Flexible Electromagnetic Absorber Sheets Combined with a Metal Layer.

Victoria J, Suarez A, Torres J, Martinez PA, Alcarria A, Martos J, Garcia-Olcina R, Soret J, Muetsch S, Gerfer A.

Materials (Basel). 2018 Sep 4;11(9). pii: E1612. doi: 10.3390/ma11091612.

6.

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C.

Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29.

PMID:
30025278
7.

Characterization of Different Cable Ferrite Materials to Reduce the Electromagnetic Noise in the 2-150 kHz Frequency Range.

Suarez A, Victoria J, Alcarria A, Torres J, Martinez PA, Martos J, Soret J, Garcia-Olcina R, Muetsch S.

Materials (Basel). 2018 Jan 23;11(2). pii: E174. doi: 10.3390/ma11020174.

8.

Role for cementoplasty in intra-articular distal radius fractures: Cadaver study and application to arthroscopy.

Fontaine V, Grunberg M, Soret J, El-Youssef K, Gayet LE, Taberne R.

Orthop Traumatol Surg Res. 2018 Feb;104(1):105-108. doi: 10.1016/j.otsr.2017.08.010. Epub 2017 Sep 18.

9.

A new cis-acting motif is required for the axonal SMN-dependent Anxa2 mRNA localization.

Rihan K, Antoine E, Maurin T, Bardoni B, Bordonné R, Soret J, Rage F.

RNA. 2017 Jun;23(6):899-909. doi: 10.1261/rna.056788.116. Epub 2017 Mar 3.

10.

Place du ruxolitinib dans la stratégie thérapeutique des syndromes myéloprolifératifs.

Soret J, Kiladjian JJ.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S29-38. doi: 10.1016/S0007-4551(16)30143-6. Review. French.

PMID:
27494970
11.

Impact of acute and chronic graft-versus-host disease on human B-cell generation and replication.

Glauzy S, Soret J, Fournier I, Douay C, Moins-Teisserenc H, Peffault de Latour R, Maki G, Robin M, Socié G, Toubert A, Clave E.

Blood. 2014 Oct 9;124(15):2459-62. doi: 10.1182/blood-2014-05-573303. Epub 2014 Sep 2.

PMID:
25185266
12.

Characterization and in vivo functional analysis of the Schizosaccharomyces pombe ICLN gene.

Barbarossa A, Antoine E, Neel H, Gostan T, Soret J, Bordonné R.

Mol Cell Biol. 2014 Feb;34(4):595-605. doi: 10.1128/MCB.01407-13. Epub 2013 Dec 2.

13.

Genome-wide identification of mRNAs associated with the protein SMN whose depletion decreases their axonal localization.

Rage F, Boulisfane N, Rihan K, Neel H, Gostan T, Bertrand E, Bordonné R, Soret J.

RNA. 2013 Dec;19(12):1755-66. doi: 10.1261/rna.040204.113. Epub 2013 Oct 23.

14.

Implication of the SMN complex in the biogenesis and steady state level of the signal recognition particle.

Piazzon N, Schlotter F, Lefebvre S, Dodré M, Méreau A, Soret J, Besse A, Barkats M, Bordonné R, Branlant C, Massenet S.

Nucleic Acids Res. 2013 Jan;41(2):1255-72. doi: 10.1093/nar/gks1224. Epub 2012 Dec 5.

15.

Novel wireless sensor system for dynamic characterization of borehole heat exchangers.

Martos J, Montero Á, Torres J, Soret J, Martínez G, García-Olcina R.

Sensors (Basel). 2011;11(7):7082-94. doi: 10.3390/s110707082. Epub 2011 Jul 8.

16.

Francisella tularensis meningitis.

Contentin L, Soret J, Zamfir O, Gontier O, Lherm T, Hamrouni M, Ouchenir A, Monchamps G, Kalfon P.

Med Mal Infect. 2011 Oct;41(10):556-8. doi: 10.1016/j.medmal.2011.07.004. Epub 2011 Aug 9. No abstract available.

PMID:
21831551
17.

An ab initio evaluation of the local effective interactions in the NaxCoO2 family.

Landron S, Soret J, Lepetit MB.

J Phys Condens Matter. 2010 Sep 1;22(34):345603. doi: 10.1088/0953-8984/22/34/345603. Epub 2010 Aug 3.

PMID:
21403259
18.

Impaired minor tri-snRNP assembly generates differential splicing defects of U12-type introns in lymphoblasts derived from a type I SMA patient.

Boulisfane N, Choleza M, Rage F, Neel H, Soret J, Bordonné R.

Hum Mol Genet. 2011 Feb 15;20(4):641-8. doi: 10.1093/hmg/ddq508. Epub 2010 Nov 23.

PMID:
21098506
19.

Specific splicing defects in S. pombe carrying a degron allele of the Survival of Motor Neuron gene.

Campion Y, Neel H, Gostan T, Soret J, Bordonné R.

EMBO J. 2010 Jun 2;29(11):1817-29. doi: 10.1038/emboj.2010.70. Epub 2010 Apr 16.

20.

A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects.

Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, Wang Q, Buisine MP, Soret J, Tazi J, Frébourg T, Tosi M.

Hum Mutat. 2008 Dec;29(12):1412-24. doi: 10.1002/humu.20796.

PMID:
18561205
21.

Characterization of a short isoform of human Tgs1 hypermethylase associating with small nucleolar ribonucleoprotein core proteins and produced by limited proteolytic processing.

Girard C, Verheggen C, Neel H, Cammas A, Vagner S, Soret J, Bertrand E, Bordonné R.

J Biol Chem. 2008 Jan 25;283(4):2060-9. Epub 2007 Nov 26.

22.
23.

The SR family proteins B52 and dASF/SF2 modulate development of the Drosophila visual system by regulating specific RNA targets.

Gabut M, Dejardin J, Tazi J, Soret J.

Mol Cell Biol. 2007 Apr;27(8):3087-97. Epub 2007 Feb 5.

24.

SR proteins as potential targets for therapy.

Soret J, Gabut M, Tazi J.

Prog Mol Subcell Biol. 2006;44:65-87. Review.

PMID:
17076265
25.

[Anastomosis of ectopic trifid ureter into the prostatic urethra with ureteropelvic reflux].

André D, Hamie F, Chautard D, Colombel P, Soret JY.

Prog Urol. 2006 Apr;16(2):211-4. Review. French.

PMID:
16734249
26.

Chaotic dynamics of superconductor vortices in the plastic phase.

Olive E, Soret JC.

Phys Rev Lett. 2006 Jan 20;96(2):027002. Epub 2006 Jan 17.

PMID:
16486618
27.

Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.

Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, Fic W, Divita G, Rivalle C, Dauzonne D, Nguyen CH, Jeanteur P, Tazi J.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8764-9. Epub 2005 Jun 6.

28.
29.

Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives.

Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, Baldeyrou B, Lansiaux A, Bailly C.

Mol Pharmacol. 2005 Apr;67(4):1186-94. Epub 2004 Dec 29.

PMID:
15625279
30.
31.

Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.

Chautard D, Dalifard I, Chassevent A, Guyetant S, Daver A, Vielle B, Soret JY.

Urology. 2004 Jun;63(6):1055-60.

PMID:
15183949
32.

Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.

Solier S, Lansiaux A, Logette E, Wu J, Soret J, Tazi J, Bailly C, Desoche L, Solary E, Corcos L.

Mol Cancer Res. 2004 Jan;2(1):53-61.

33.

Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I.

Soret J, Gabut M, Dupon C, Kohlhagen G, Stévenin J, Pommier Y, Tazi J.

Cancer Res. 2003 Dec 1;63(23):8203-11.

34.

Numerical simulation evidence of dynamical transverse meissner effect and moving bose glass phase.

Olive E, Soret JC, Le Doussal PL, Giamarchi T.

Phys Rev Lett. 2003 Jul 18;91(3):037005. Epub 2003 Jul 18.

PMID:
12906443
35.

Phosphorylation-dependent control of the pre-mRNA splicing machinery.

Soret J, Tazi J.

Prog Mol Subcell Biol. 2003;31:89-126. Review. No abstract available.

PMID:
12494764
36.

[Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].

Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, Vielle B, Soret JY, Passagot J, Courte C, Daver A.

Prog Urol. 2002 Jun;12(3):421-8. French.

PMID:
12189749
37.

Response to tilted magnetic fields in Bi(2)Sr(2)CaCu(2)O(8) with columnar defects: evidence for transverse Meissner effect.

Ta Phuoc V, Olive E, De Sousa R, Ruyter A, Ammor L, Soret JC.

Phys Rev Lett. 2002 May 6;88(18):187002. Epub 2002 Apr 18.

PMID:
12005712
38.

[Standards, Options, and Recommendations for brachytherapy in patients with prostate cancer: efficacy and toxicity].

Pommier P, Villers A, Bataillard A, Brune D, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Daver A, Fontaine E, Guilloneau B, Haillot O, Lagrange JL, Molinié V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnitch D, Ravery V, Richaud P, Rossi D, Soret JY.

Cancer Radiother. 2001 Dec;5(6):770-86. French.

PMID:
11797299
39.

Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.

Pilch B, Allemand E, Facompré M, Bailly C, Riou JF, Soret J, Tazi J.

Cancer Res. 2001 Sep 15;61(18):6876-84.

40.

SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs.

Sureau A, Gattoni R, Dooghe Y, Stévenin J, Soret J.

EMBO J. 2001 Apr 2;20(7):1785-96.

41.

Distinctive features of Drosophila alternative splicing factor RS domain: implication for specific phosphorylation, shuttling, and splicing activation.

Allemand E, Gattoni R, Bourbon HM, Stevenin J, Cáceres JF, Soret J, Tazi J.

Mol Cell Biol. 2001 Feb;21(4):1345-59.

42.

Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.

Chautard D, Daver A, Bocquillon V, Verriele V, Colls P, Bertrand G, Soret JY.

Eur Urol. 2000 Dec;38(6):686-90.

PMID:
11111185
43.

[Is it possible to define a threshold for free PSA index that is useful in the daily practice of urology?].

Chautard D, Bocquillon V, Daver A, Colls P, Soret JY.

Prog Urol. 2000 Sep;10(4):571-7. French.

PMID:
11064899
44.

Values for the free to total prostate-specific antigen ratio as a function of age: necessity of reference range validation.

Chautard D, Daver A, Mermod B, Tichet A, Bocquillon V, Soret J.

Eur Urol. 1999 Sep;36(3):181-6.

PMID:
10449999
45.

[Flow cytometry in cancer of the bladder].

Chassevent A, Allain YM, Chautard D, Larra F, Lépinard V, Soret JY.

Cancer Radiother. 1998 Apr;2 Suppl 1:12s-15s. Review. French.

PMID:
9749070
47.

Characterization of SRp46, a novel human SR splicing factor encoded by a PR264/SC35 retropseudogene.

Soret J, Gattoni R, Guyon C, Sureau A, Popielarz M, Le Rouzic E, Dumon S, Apiou F, Dutrillaux B, Voss H, Ansorge W, Stévenin J, Perbal B.

Mol Cell Biol. 1998 Aug;18(8):4924-34.

48.

Characterization of multiple alternative RNAs resulting from antisense transcription of the PR264/SC35 splicing factor gene.

Sureau A, Soret J, Guyon C, Gaillard C, Dumon S, Keller M, Crisanti P, Perbal B.

Nucleic Acids Res. 1997 Nov 15;25(22):4513-22.

49.

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.

Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.

Eur Urol. 1997;32(4):391-5; discussion 395-6.

PMID:
9412794
50.

Adjuvant treatment with IL-2 or interferon-alpha in renal cell carcinoma: a French multicentric study.

Soret JY, Escudier B.

Cancer Biother Radiopharm. 1996 Oct;11(5):301-2. No abstract available.

PMID:
10851508

Supplemental Content

Support Center